Compass Pathways PLC
CMPS
查看详细走势图
6.680USD
-0.165-2.41%
收盘 12/26, 16:00（美东）报价延迟15分钟
641.29M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.41%
5天
+4.87%
1月
+27.72%
6月
+141.16%
今年开始到现在
+76.72%
1年
+67.42%
查看详细走势图
TradingKey Compass Pathways PLC股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Compass Pathways PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
10
位分析师
买入
评级
17.000
目标均价
+169.84%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Compass Pathways PLC亮点
亮点风险
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-3.61，处于3年历史低位
机构减仓
最新机构持股53.36M股，环比减少17.31%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值3.43K
活跃度降低
近期活跃度降低，过去20天平均换手率0.31
Compass Pathways PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Compass Pathways PLC简介
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
公司代码CMPS
公司Compass Pathways PLC
CEONath (Kabir)
网址https://compasspathways.com/
常见问题
Compass Pathways PLC(CMPS)的当前股价是多少？
Compass Pathways PLC(CMPS)的当前股价是 6.680。
Compass Pathways PLC的股票代码是什么？
Compass Pathways PLC的股票代码是CMPS。
Compass Pathways PLC股票的52周最高点是多少？
Compass Pathways PLC股票的52周最高点是7.150。
Compass Pathways PLC股票的52周最低点是多少？
Compass Pathways PLC股票的52周最低点是2.250。
Compass Pathways PLC的市值是多少？
Compass Pathways PLC的市值是641.29M。
Compass Pathways PLC的净利润是多少？
Compass Pathways PLC的净利润为-155.12M。
现在Compass Pathways PLC(CMPS)的股票是买入、持有还是卖出？
根据分析师评级，Compass Pathways PLC(CMPS)的总体评级为买入，目标价格为17.000。
Compass Pathways PLC(CMPS)股票的每股收益（EPS TTM）是多少
Compass Pathways PLC(CMPS)股票的每股收益（EPS TTM）是-2.724。
相关品种
